Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B-ALL: early-phase trial registry
6 of 8 indexed B-ALL trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 6 currently recruiting · #2,176 of 28,707 conditions by registered trial count
B-ALL: 8 US clinical trials tracked, 6 recruiting.
B-ALL is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition b-all
OPEN 6 | RECR 75% | LATE 0 | EARLY 5 | RANK #2176 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adolescent Idiopathic Scoliosis (75% recruiting · 8 trials)
B-ALL lists 6 open slots (75% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for B-ALL on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
B-ALL is recruiting above its size-band peers.
6 of 8 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates B-ALL research.
National Cancer Institute (NCI) accounts for 3 of 8 trials (37.5%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical B-ALL enrolment sits around 100 participants.
Median target enrolment is 100 among the 8 trials that report a genuine target (sentinel values excluded). 4 of those (50%) plan for fewer than 100 participants.
-
B-ALL research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT05442515
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
St. Jude Children's Research Hospital
NCT04318678
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
St. Jude Children's Research Hospital
NCT06579469
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
National Cancer Institute (NCI)
NCT05621291
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
University of Chicago
NCT06785324
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04512716
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT02315612
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
NCT04088890
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on B-ALL records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on B-ALL trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this B-ALL page
8 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 B-ALL trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most B-ALL trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B-ALL condition card totals 8 registered trials; most-linked intervention Fludarabine; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.